Biogen Inc (BIIB)
173.79
-0.21
(-0.12%)
USD |
NASDAQ |
Nov 01, 16:00
175.18
+1.39
(+0.80%)
After-Hours: 20:00
Biogen Enterprise Value: 29.92B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 29.92B |
| October 31, 2024 | 29.95B |
| October 30, 2024 | 31.00B |
| October 29, 2024 | 31.33B |
| October 28, 2024 | 31.55B |
| October 25, 2024 | 31.07B |
| October 24, 2024 | 31.38B |
| October 23, 2024 | 31.25B |
| October 22, 2024 | 31.68B |
| October 21, 2024 | 31.50B |
| October 18, 2024 | 32.30B |
| October 17, 2024 | 32.21B |
| October 16, 2024 | 32.13B |
| October 15, 2024 | 32.50B |
| October 14, 2024 | 32.50B |
| October 11, 2024 | 32.04B |
| October 10, 2024 | 32.07B |
| October 09, 2024 | 31.66B |
| October 08, 2024 | 31.16B |
| October 07, 2024 | 31.31B |
| October 04, 2024 | 31.65B |
| October 03, 2024 | 31.52B |
| October 02, 2024 | 32.09B |
| October 01, 2024 | 32.39B |
| September 30, 2024 | 32.84B |
| Date | Value |
|---|---|
| September 27, 2024 | 32.74B |
| September 26, 2024 | 32.58B |
| September 25, 2024 | 31.92B |
| September 24, 2024 | 32.66B |
| September 23, 2024 | 32.91B |
| September 20, 2024 | 33.42B |
| September 19, 2024 | 33.73B |
| September 18, 2024 | 33.16B |
| September 17, 2024 | 33.25B |
| September 16, 2024 | 33.45B |
| September 13, 2024 | 32.88B |
| September 12, 2024 | 33.21B |
| September 11, 2024 | 33.38B |
| September 10, 2024 | 33.61B |
| September 09, 2024 | 33.41B |
| September 06, 2024 | 33.63B |
| September 05, 2024 | 33.78B |
| September 04, 2024 | 34.24B |
| September 03, 2024 | 34.22B |
| August 30, 2024 | 34.21B |
| August 29, 2024 | 34.22B |
| August 28, 2024 | 34.13B |
| August 27, 2024 | 34.00B |
| August 26, 2024 | 34.22B |
| August 23, 2024 | 34.24B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
29.92B
Minimum
Nov 01 2024
67.15B
Maximum
Jun 10 2021
42.79B
Average
42.07B
Median
Jun 29 2023
Enterprise Value Benchmarks
| Eli Lilly and Co | 805.11B |
| Ionis Pharmaceuticals Inc | 5.311B |
| Sage Therapeutics Inc | -199.06M |
| Regeneron Pharmaceuticals Inc | 84.89B |
| Moderna Inc | 12.51B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 388.50M |
| Revenue (Quarterly) | 2.466B |
| Total Expenses (Quarterly) | 1.969B |
| EPS Diluted (Quarterly) | 2.66 |
| Gross Profit Margin (Quarterly) | 74.10% |
| Profit Margin (Quarterly) | 15.76% |
| Earnings Yield | 6.37% |
| Operating Earnings Yield | 8.78% |
| Normalized Earnings Yield | 6.918 |